Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.85 +0.05 (+0.19%)
Official Closing Price Updated: 7:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
Via AB Newswire
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
Creative Biolabs: The Way ADCs Are Made Has Changed
Via Get News
Pfizer Inc. (NYSE: PFE) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
News headline image
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
News headline image
3 Stocks That Suddenly Drew in Options Traders
Three discounted stocks caught the attention of call option buyers last week, and they have Wall Street analysts to back them through double-digit upside. 
Via MarketBeat
News headline image
Study Questions Serious Flaws in $35 Million Antidepressant Research
CCHR says millions of taxpayer dollars are wasted on psychotropic drug research later found to be flawed and harmful to consumersLOS ANGELES - March 22, 2024 - PRLog -- Researchers have reanalyzed data... 
Via PRLog
Topics Fraud
News headline image
Generis Welcomes Max Kelleher as New Chief Executive Officer
LONDON - May 14, 2024 - PRLog -- Generis, creator of the cloud data, content, and business process management platform CARA™, today announced that Max Kelleher will be stepping into the role of Chief... 
Via PRLog
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
News headline image
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
News headline image
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
News headline image
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
News headline image
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
News headline image
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
News headline image
3 Bargain Stocks Near 52-week Lows
Three undeniable bargains came into play after the market's disappointment sell off, investors still have double-digit upside ahead of them in these names 
Via MarketBeat
Topics Economy
News headline image
Pfizer Declares Second-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Pneumococcal Pneumonia Vaccination Can Save Your Life
Via StatePoint Media
QFunction: Cybersecurity Company Announces Launch of Customized AI Solutions
Via Press Release Distribution Service
Topics Artificial Intelligence
News headline image
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
From Pfizer Inc.
Via Business Wire
News headline image
4 Dividend Aristocrats Trading at a Discount
Near the end of the first quarter, a shift toward more defensive sectors occurred, prompting investors to buy fair-value dividend stocks like MO, T, F, and PFE 
Via MarketBeat
Topics Artificial Intelligence Economy
Groundbreaking Documentary ‘Project Whistleblower’ Pulls Back the Curtain on Corporate Misconduct
Via Press Release Distribution Service
Topics Whistleblower
News headline image
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
News headline image
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.